Firebrick Pharma Limited (FRE) AI Stock Analysis

• Market Cap: AU$13.89M
• Dividend Yield: N/A
• Average Volume (3M): 91.61K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.74
• Revenue Growth: 1920.53%
• EPS Growth: -89.39%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): N/A
• Shares Outstanding: 252,479,080
• 10 Day Avg. Volume: 136,612
• 30 Day Avg. Volume: 91,607
• PEG Ratio: -0.06
• Price to Book (P/B): 8.38
• Price to Sales (P/S): 44.43
• P/FCF Ratio: -7.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: AU$0.06 ▲(16.00% Upside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is driven primarily by weak financial performance (sharp revenue decline, persistent large losses, and ongoing negative free cash flow). Technical indicators also point to a sustained downtrend with negative momentum. The balance sheet is a mitigating factor due to zero reported debt, but losses and cash burn remain the dominant risks.

Positive Factors

Low leverage / strong balance sheet flexibility

Zero reported debt and a 0 debt-to-equity ratio materially reduce financial risk and preserve strategic optionality. Over a 2–6 month horizon this gives management flexibility to fund clinical or commercial activities via equity or partnerships without immediate refinancing pressure, cushioning the cash-burn runway.

Positive product gross margin

A roughly 36% gross margin demonstrates the underlying product economics can be healthy. If the company stabilises revenue and controls operating expenses, this margin provides a viable path to operating leverage and eventual profitability, making the business model structurally more defensible.

Reduced cash burn trend

Operating and free cash outflows have meaningfully declined versus 2023, indicating improving cost discipline or operational efficiencies. Sustaining this trend would extend runway, lower near-term financing needs, and increase the probability management can execute commercial or regulatory milestones without immediate dilution.

Negative Factors

Severe revenue decline

A ~74% year-over-year revenue drop signals weak product traction, demand disruption, or concentration risk. Such a steep decline undermines scalability, reduces pricing power, and makes it harder to absorb fixed costs. Recovery will require durable improvements in sales execution or new product uptake.

Persistent large losses and negative cash flow

Consistent operating losses and negative free cash flow mean the business is not self-funding. Continued cash burn forces reliance on external capital or partnerships, which can dilute shareholders and constrain investment in commercialization or R&D, limiting long-term value creation.

Very weak returns on equity and dilution risk

A ~-169% ROE and declining equity reflect sustained capital destruction. This pattern increases the likelihood of future equity raises or dilutive financings to sustain operations, compressing shareholder value and reducing long-term return potential absent a clear path to profitability.

Firebrick Pharma Limited Business Overview & Revenue Model

Company Description

Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.

How the Company Makes Money

Firebrick Pharma Limited generates revenue through the sale and licensing of its pharmaceutical products. The company's primary revenue streams include the commercialization of its proprietary formulations and partnerships with healthcare providers and pharmaceutical distributors. Additionally, Firebrick Pharma may engage in collaborative research and development agreements, which can provide milestone payments and royalties. Significant partnerships with healthcare institutions and research organizations contribute to its earnings by expanding market reach and enhancing product development.

Firebrick Pharma Limited Financial Statement Overview

Summary

Income statement and cash flow are very weak: revenue fell sharply in 2025 (down ~74% vs. 2024), operating losses remain large with a deeply negative net margin (~-898%), and operating/free cash flow are consistently negative (2025 FCF about -1.9M). The main offsetting positive is the balance sheet: zero reported debt and a 0 debt-to-equity ratio reduce financial risk, though losses are driving very negative ROE (~-169%) and pressure on equity.

Income Statement

Revenue has been highly volatile, with a sharp drop in 2025 (annual revenue down ~74% vs. 2024) after a small base in prior years. Profitability remains weak: despite a positive gross margin in 2025 (~36%), operating losses are large and persistent, and net margin is deeply negative (about -898% in 2025). Overall, the company is still far from demonstrating a stable, scalable earnings profile.

Balance Sheet

The balance sheet is a relative strength: total debt is reported at zero in recent years and the debt-to-equity ratio is 0. This low leverage reduces financial risk and provides flexibility. The key weakness is ongoing losses driving negative returns on equity (notably ~-169% in 2025), and equity has declined from earlier years, indicating sustained dilution/burn risk if losses continue.

Cash Flow

Cash generation remains a concern. Operating cash flow and free cash flow are consistently negative across all periods, indicating the business is not self-funding. There is improvement versus 2023 (cash burn reduced meaningfully by 2024–2025), but 2025 still shows sizable cash outflows (operating cash flow about -1.8M; free cash flow about -1.9M). Cash flow broadly tracks losses, suggesting limited near-term ability to finance operations internally.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	381.71K	293.42K	14.52K	830.00	4.12K	422.00K
Gross Profit	-260.68K	104.82K	-22.78K	830.00	4.12K	421.48K
EBITDA	-2.45M	-2.86M	-1.17M	-6.81M	-4.86M	-2.86M
Net Income	-2.45M	-2.63M	-1.18M	-6.80M	-3.80M	-2.44M
Balance Sheet
Total Assets	2.28M	1.83M	2.41M	2.98M	8.73M	11.77M
Cash, Cash Equivalents and Short-Term Investments	1.44M	983.35K	824.78K	2.35M	7.14M	11.16M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	341.73K	271.28K	291.07K	506.44K	450.10K	214.80K
Stockholders Equity	1.94M	1.56M	2.12M	2.48M	8.28M	11.55M
Cash Flow
Free Cash Flow	-2.25M	-1.86M	-2.35M	-5.78M	-4.23M	-1.95M
Operating Cash Flow	-2.24M	-1.78M	-2.34M	-5.78M	-4.20M	-1.94M
Investing Cash Flow	-16.50K	-82.98K	-134.00	-1.62K	-32.54K	-16.07K
Financing Cash Flow	2.78M	2.02M	815.21K	996.65K	10.23M	3.01M

Firebrick Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:FRE, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 55.95 is Neutral, neither overbought nor oversold. The STOCH value of 2.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:FRE.

Firebrick Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RCE	52 Neutral	AU$156.16M	-4.74	―	―	―	0.66%
ALA	52 Neutral	AU$98.99M	-11.71	-47.98%	―	700.00%	26.88%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BOT	44 Neutral	AU$124.21M	-1.20	-90.93%	―	456.50%	-457.14%
FRE	42 Neutral	AU$13.89M	-5.19	-143.50%	―	1920.53%	-89.39%
HXL	40 Underperform	AU$2.17M	-9.29	-28.49%	―	―	46.43%
IIQ	38 Underperform	AU$49.27M	-5.69	-37.78%	―	2.33%	12.50%

Firebrick Pharma Limited Corporate Events

Firebrick Pharma Revenue Slides as Auditor Flags Going-Concern Risk

Firebrick Pharma has reported a sharp fall in half-year revenue to A$63,267 for the period ended 31 December 2025, down nearly 68% from a year earlier, while narrowing its after-tax loss to A$1.26 million, a 12.7% improvement. Net tangible assets per share edged up to 0.77 cents from 0.71 cents, no dividends were declared, and the company’s auditor highlighted a material uncertainty over Firebrick’s ability to continue as a going concern, underscoring ongoing financial pressures despite modest balance sheet gains.

The group reported no acquisitions or disposals of controlled entities, and there were no associate or joint venture interests to affect the results. The financial statements were prepared on a going concern basis, but the auditor’s emphasis of matter signals elevated risk for shareholders and creditors if Firebrick cannot secure sufficient funding or improve operating performance in the medium term.

The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.

Firebrick Pharma Issues 1 Million Unlisted Options to Support Capital Structure

Firebrick Pharma Limited has issued 1,000,000 unlisted options exercisable at $0.15 and expiring on 10 February 2030. The options, which form part of previously announced transactions and are not intended to be quoted on the ASX, represent a further step in the company’s use of equity-based instruments to support its capital structure and align stakeholder incentives.

The issuance of these long-dated options may provide additional flexibility in future funding while limiting immediate dilution for existing shareholders. By opting for unquoted options, Firebrick can structure targeted incentives or commitments without impacting the liquidity profile of its quoted securities on the main market.

The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.

Firebrick Pharma Plans Issue of 1 Million Unlisted Options

Firebrick Pharma Limited has notified the ASX of a proposed issue of up to 1,000,000 unlisted options as part of a placement or similar capital-raising mechanism. The options will be exercisable at $0.15 and are scheduled to expire on 10 February 2030, indicating a long-dated incentive structure that may support future funding flexibility and align stakeholder interests over the medium term.

The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.

Firebrick Pharma adds seasoned North American director to drive global Nasodine growth

Firebrick Pharma has appointed North America-based executive Al Moghaddam as a Non-Executive Director, effective 1 March 2026, following an international search to fill a board vacancy. The company will grant him 1,000,000 options with a four-year expiry at an exercise price of $0.15 per share as part of his appointment.

Moghaddam brings three decades of global pharma and healthcare experience, including senior roles at major companies and leading a specialty pharmaceutical startup to a dual TSX and NASDAQ listing. Firebrick expects his expertise in global commercialization and U.S. consumer health distribution to help drive Nasodine’s commercial growth in the U.S. and other international markets, strengthening governance and strategic oversight for shareholders.

The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.

Firebrick Pharma Expands Nasodine Range and International Footprint as Sales and Cost Discipline Improve

Firebrick Pharma reported solid operational progress in the December 2025 quarter, highlighted by the first expansion of its Nasodine product range with the Nasodine Throat Spray moving into commercial manufacturing, securing Australian approval for export and launching into Singapore with initial promotion to government hospitals and online consumer sales. The company outlined a clear international growth strategy, including expanded promotion in the US, broader pharmacy distribution in Singapore, the first orders for Fiji, a regulatory review underway in the Philippines and active exploration of additional Southeast Asian and Middle Eastern markets, while user survey data showed very high satisfaction with Nasodine Nasal Spray and financial discipline delivered lower operating costs and 15% year-on-year growth in quarterly cash sales, positioning Firebrick for reduced cash burn as revenues scale.

The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.

Firebrick Pharma Secures First Fiji Order for Nasodine Throat Spray

Firebrick Pharma has secured an initial order for 216 units of its newly launched Nasodine Throat Spray from Fiji and South Pacific licensee Makans Ltd, marking the product’s entry into the Fiji market shortly after its rollout in Singapore. The shipment, supplied by Australian manufacturer Probiotec, will support promotional activities to doctors and pharmacists starting in February, with Makans positioning the throat spray as a complementary extension to Nasodine Nasal Spray for inactivating viruses, including Covid, and killing bacteria linked to respiratory infections—an early step in building the Nasodine brand as a household name across Fiji and the wider South Pacific region.

The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.

Firebrick Pharma Clears Key Regulatory Hurdle for Nasodine in Philippine Market

Firebrick Pharma has confirmed that the registration process for its Nasodine Nasal Spray in the Philippines has advanced, with the country’s Food and Drug Administration accepting the product dossier following pre-assessment and commencing a formal review expected to take at least six months. The move marks a key step toward potential 2026 approval in a large pharmaceutical market where Firebrick is partnered with and partly backed by SV More Pharma, and benefits from a regulatory pathway that treats Nasodine as a disinfectant spray manufactured locally, allowing submission based on a manufacturing dossier without requiring clinical efficacy studies.

The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.